Bayer's Twin Headwinds: A Shifting Court Calendar and a Stinging Verdict on Capital Efficiency

Bayer shares fall 2.1% as US court postpones Roundup settlement and analyst podcast flags poor returns and goodwill overhang.

The market's verdict on Bayer arrived from two directions at once this week, and neither was flattering. The shares slipped to €48.18, down 2.1 percent, as investors digested a postponed court hearing in the US glyphosate litigation and a newly launched podcast that took a wrecking ball to the company's balance-sheet discipline. The double dose of negative news left the stock trading roughly eleven percent beneath its 52-week high of €53.86, a level touched only in early July.

The immediate trigger for the sell-off was procedural rather than substantive. A Missouri court had been expected to grant final approval to the multibillion-dollar class-action settlement on August 19, but that hearing has now been pushed back to September 14. The delay itself is not what has unnerved the market — it is the jurisdictional fight bubbling beneath the surface. Plaintiffs' attorneys are pushing to have the case moved to California, while Bayer is digging in on Missouri as the proper venue. Until that question is resolved, the timeline for locking in legal certainty around the Roundup claims remains genuinely up in the air.

Should Missouri retain jurisdiction, the settlement can be legally secured without much further ado. A transfer to California, however, would reopen the door to fresh delays and potentially shift the negotiating dynamics entirely. That binary outcome explains why the stock is now hovering between support at its 50-day moving average and resistance at the 52-week high, with volatility likely to persist until the venue question is settled.

The second piece of negative news came from an unexpected corner: the debut episode of a new podcast called "Warren's Watchlist," in which analyst Warren Wise trained his lens on Bayer alongside SAP. The verdict was blunt. Wise argues that Bayer's return on invested capital has now trailed its cost of capital for three consecutive years — meaning the company is, on a purely arithmetic basis, destroying value rather than creating it. That is a charge aimed squarely at long-term investors who have been willing to look past near-term legal noise.

The analysis goes further, flagging a structural imbalance that has its roots in the Monsanto acquisition: Bayer's reported goodwill now exceeds its total equity. That configuration is widely regarded as a red flag, a reminder of how profoundly the $63 billion takeover continues to shape the balance sheet. Combined with the group's elevated debt load, the podcast's five-tier assessment places Bayer on its lowest rung.

None of this is to dismiss the genuine legal progress Bayer has made. The company's victory before the US Supreme Court in the glyphosate case, secured in recent weeks, was a meaningful milestone and has prompted several analysts to lift their price targets. But as Wise's analysis correctly notes, a single courtroom win does not cure a structural problem. The capital-efficiency gap and the goodwill-overhang exist independently of any individual legal outcome.

The fundamental picture, stripped of the day-to-day noise, is nonetheless not without its supporters. The stock still trades 18 percent above its 200-day average, a signal that the longer-term uptrend remains technically intact. Year-to-date, Bayer has gained 30 percent, and over the past twelve months the advance stands at 73 percent. Those are not the numbers of a company in terminal decline, whatever the balance-sheet critics may say.

Still, the distance to the 52-week high is a reminder of how much ground has been given back. The repeated postponements of the settlement hearing suggest the path to final approval is more tortuous than the market had hoped, and the jurisdictional challenge adds a layer of uncertainty that did not exist a month ago.

The next concrete date on the calendar is September 14, when the Missouri court is scheduled to hear the settlement approval motion. The one after that is November 3, when Bayer reports third-quarter results — the next opportunity for management to demonstrate that the operational engine can generate returns that justify the capital employed. Until then, the debate around Bayer will remain split between those who see a deeply undervalued franchise with legal clouds lifting and those who see a balance sheet that no amount of courtroom success can repair.